ReviewClinics and practice2024
A Narrative Review of Current Knowledge on Cutaneous Melanoma.
Review in Clinics and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 20 citations in OpenAlex.
- Regional Variations in Melanoma Histologic Characteristics: A Multicenter Cohort Study from Two Southeastern European Countries.Journal of clinical medicine · 2026Article
- Genetic analysis of genes GSTP1, PTEN, and TP53 SNPs in non-melanoma skin cancer patients.Journal of cancer research and clinical oncology · 2026Article
- Unraveling the Enigma of Melanoma Brain Metastasis: New Molecular Insights and Therapeutic Directions.International journal of molecular sciences · 2026Review
- Global Burden and Drivers of Cutaneous Malignant Melanoma Among Women Aged 55 and Older.International journal of women's health · 2026Article
- Targeting YAP-TEAD Interaction with Honokiol to Inhibit Melanoma Progression and Metastasis.Biomolecules & therapeutics · 2026Article
- Local Delivery of Ginger ExtractCurrent drug delivery · 2026Article
- Differences of clinical features, prognosis and genetic mutations in Chinese patients with malignant melanoma and additional primary tumours.Annals of medicine · 2025Article
- Comparative Insights into Cutaneous, Mucosal, and Vulvovaginal Melanomas: Biology, Targeted Therapies, and Survival with a Focus on Immune Checkpoint Inhibitors.Journal of personalized medicine · 2025Review
- Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF-MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib.Journal of clinical medicine · 2025Review
- Nanocarrier mediated DOX/siRNA targeted co-delivery for synergistic treatment of cutaneous melanoma in outdoor athletes.Scientific reports · 2025Article
- Inter-Relationship Between Melanoma Vemurafenib Tolerance Thresholds and Metabolic Pathway Choice.Cells · 2025Article
- Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.Cancer management and research · 2025Article
- Efficacy Assessment and Prognostic Value of Inflammatory Markers in Patients with Stage IV Acral and Cutaneous Melanoma Receiving PD-1 Inhibitors.Journal of inflammation research · 2025Article
- Integrating Machine Learning Algorithms to Construct a Triaptosis-Related Prognostic Model in Melanoma.Cancer management and research · 2025Article
- Peptide Design for Enhanced Anti-Melanogenesis: Optimizing Molecular Weight, Polarity, and Cyclization.Drug design, development and therapy · 2025Review
- HSPA4 Expression is Correlated with Melanoma Cell Proliferation, Prognosis, and Immune Regulation.Clinical, cosmetic and investigational dermatology · 2024Article
- Unraveling the Obesity Paradox: Exploring the Impact of Body Weight on Cutaneous Melanoma Prognosis in Asian Population.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Novel Prognostic Markers for Skin Cutaneous Melanoma.Clinical, cosmetic and investigational dermatology · 2024Article
- Impact on Survival with Immunotherapy and Evaluation of Biomarkers in Peruvian Patients with Advanced Melanoma.OncoTargets and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous melanoma is a public health problem. Efforts to reduce its incidence have failed, as it continues to increase. In recent years, many risk factors have been identified. Numerous diagnostic systems exist that greatly assist in early clinical diagnosis. The histopathological aspect illustrates the grim nature of these cancers. Currently, pathogenic pathways and the tumor microclimate are key to the development of therapeutic methods. Revolutionary therapies like targeted therapy and immune checkpoint inhibitors are starting to replace traditional therapeutic methods. Targeted therapy aims at a specific molecule in the pathogenic chain to block it, stopping cell growth and dissemination. The main function of immune checkpoint inhibitors is to boost cellular immunity in order to combat cancer cells. Unfortunately, these therapies have different rates of effectiveness and side effects, and cannot be applied to all patients. These shortcomings are the basis of increased incidence and mortality rates. This study covers all stages of the evolutionary sequence of melanoma. With all these data in front of us, we see the need for new research efforts directed at therapies that will bring greater benefits in terms of patient survival and prognosis, with fewer adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.